FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection By Ogkologos - March 20, 2025 735 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ReNeu study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer EMA Recommends Extension of Indications for Selpercatinib MOST POPULAR KRASG12 Mutations Are Biomarkers for Reduced Overall Survival Benefit of Treatment... March 14, 2023 Kids Facing Difficult Medical Diagnoses Take Train To The ‘North Pole’... December 12, 2021 Remembering With Gratitude January 7, 2021 Neoadjuvant Ipilimumab Plus Nivolumab Results in Longer EFS Than Adjuvant Nivolumab... June 10, 2024 Load more HOT NEWS Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic... Adjuvant Pembrolizumab Plus Chemotherapy Improves DFS in Patients with Newly-Diagnosed, High-Risk... Mom Diagnosed With Stage III Breast Cancer While Nursing Her 9-Month-Old... Two-Step Approach Might Be An Alternative to Standard Three-Step Approach of...
